Associations - CDK12 mutation

BIOMARKER:

CDK12 mutation

Entrez ID:

51755

Related biomarkers:

Mutation

CNA

‹

›

CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2
CDK12 mutation CDK12 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	abiraterone acetate Resistant: C3 – Early Trials abiraterone acetate Resistant : C3
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	rucaparib Resistant: C3 – Early Trials rucaparib Resistant : C3
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	AST-2970 Resistant: C3 – Early Trials AST-2970 Resistant : C3
CDK12 mutation CDK12 mutation	Breast Cancer Breast Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	GnRH stimulant Resistant: C3 – Early Trials GnRH stimulant Resistant : C3
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	enzalutamide + abiraterone acetate Resistant: C3 – Early Trials enzalutamide + abiraterone acetate Resistant : C3
CDK12 mutation CDK12 mutation	Non Small Cell Lung Cancer NSCLC	olaparib Sensitive: C4 – Case Studies olaparib Sensitive : C4
CDK12 mutation CDK12 mutation	Prostate Cancer Prostate Cancer	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES